'Bad guys' among the antiparkinsonian drugs

Psychiatria Danubina

Volumn 21, Issue 1, 2009, Pages 114-118

  Pirtošek, Zvezdan ^a,b  

^a UMCL   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Adverse effects; Drugs; Parkinson's disease; Treatment

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOT DERIVATIVE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE;

BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DELIRIUM; DRUG CHOICE; DRUG EFFICACY; DYSKINESIA; ERYTHROMELALGIA; HALLUCINATION; HUMAN; HYPOMANIA; IMPULSE CONTROL DISORDER; LIVER FAILURE; LIVER TOXICITY; LUNG FIBROSIS; MANIC PSYCHOSIS; MOOD DISORDER; MORTALITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PSYCHOSIS; RECOMMENDED DRUG DOSE; RETROPERITONEAL FIBROSIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; URINE RETENTION; VALVULAR HEART DISEASE; VOMITING; XEROSTOMIA;

ANTIPARKINSON AGENTS; BENZOPHENONES; CHOLINERGIC ANTAGONISTS; COGNITION; DOPAMINE AGONISTS; HUMANS; LEVODOPA; NITROPHENOLS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELEGILINE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 63649133341     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Adler CH, Singer C, O'Brian C: Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Arch Neurol, 1998; 55: 1089-95.
2. Burchiel KJ, Anderson VC, Favre J, Hammerstad VJ: Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blindedpilot study. Neurosurgery 1999; 45: 1375-1384.
3. Ben Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ: Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomized trial and confidential inquiry. BMJ 1998, 316:1191-1196.
4. European Agency for the Evaluation of Medicinal Products (EMEA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorization for tolcapone (Tasmar). London, 29. April 2004 (http://www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf date accessed 10 January 2006).
5. Evans AH, Lees AJ: Dopamine dysregulation syndrome in Parkinson's disease Curr Opin Neurol. 2004; 17:393-398.
6. Homann CN, Wenzel K, Suppan K: Sleep attacks in patients taking dopamine agonists. BMJ 2002; 324: 1483-7.
7. Horne JA: Misconception exists about steep attacks when driving. (Letter), BMJ 2002; 324: 657
8. Katzenschlager R, Sampaio C, Costa J, Lees A: Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2002; 3:CD003735.
9. Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311:1602-7.
10. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17: S1-S166.
11. Olanow CW, Myllyla VV, Sotaniemi KA, et al: Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998; 51: 825-830.
12. Parkinson's Disease Research Group in the United Kingdom: Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307:469-72.
13. Van Camp, Flamez A, Cosyns B, et al: Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-1183.
14. van Herwaarden G, Berger HJ, Horstinh MW: Short-term memory in Parkinson's disease after withdrawal of long-term anticholinergic therapy. Clin Neuropharmacol 1993; 16: 438-443.
15. www.JimSokolove.com